NDC 68001-504

Azacitidine

Azacitidine

Azacitidine is a Subcutaneous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Bluepoint Laboratories. The primary component is Azacitidine.

Product ID68001-504_c32554cb-be86-d0d7-e053-2995a90a63a0
NDC68001-504
Product TypeHuman Prescription Drug
Proprietary NameAzacitidine
Generic NameAzacitidine
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2021-06-11
Marketing CategoryANDA /
Application NumberANDA207234
Labeler NameBluePoint Laboratories
Substance NameAZACITIDINE
Active Ingredient Strength100 mg/50mL
Pharm ClassesNucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 68001-504-54

1 VIAL, SINGLE-DOSE in 1 CARTON (68001-504-54) > 50 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date2021-06-11
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Azacitidine" or generic name "Azacitidine"

NDCBrand NameGeneric Name
0143-9606AzacitidineAzacitidine
0591-2897AzacitidineAzacitidine
0781-3253Azacitidineazacitidine
0781-9253Azacitidineazacitidine
16714-578AzacitidineAzacitidine
16714-777AzacitidineAzacitidine
16714-927AzacitidineAzacitidine
16729-306AzacitidineAzacitidine
43598-143AzacitidineAzacitidine
43598-305AzacitidineAzacitidine
43598-465AzacitidineAzacitidine
43598-678AZACITIDINEAZACITIDINE
43817-906AzacitidineAzacitidine
51991-797AzacitidineAzacitidine
55150-393AZACITIDINEAZACITIDINE
68001-313AzacitidineAzacitidine
69097-368AzacitidineAzacitidine
72485-201AZACITIDINEAZACITIDINE
63323-771AzacitidineAzacitidine
63759-0003AZACITIDINEAZACITIDINE
64679-096AZACITIDINEAZACITIDINE
67457-254AzacitidineAzacitidine
72606-558AZACITIDINEAZACITIDINE
71288-115AzacitidineAzacitidine
59572-730ONUREGazacitidine
59572-740ONUREGazacitidine
59572-102VIDAZAazacitidine
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.